ASAlexander V. Statsyuk

Alexander V. Statsyuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander V. Statsyuk has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a PROTAC Targeting Chk1

    by Sandipan Roy Chowdhury, Patrick Chuong, Victoria E. Mgbemena, Alexander Statsyuk

    A series of Chk1 degraders were designed and synthesized. The degraders were developed through the conjugation of a promiscuous kinase binder and thalidomide. One of the degraders PROTAC-2 was able to decrease Chk1 levels in a concentration-dependent manner in A375 cells. The developed probes can be useful for the development of selective and more potent Chk1 degraders.

  • Open Access

    Selective Smurf1 E3 ligase inhibitors that prevent transthiolation

    by Patrick Chuong, Alexander V Statsyuk

    Smurf1 is a HECT E3 ligase that is genetically micro-duplicated in human patients and is associated with osteoporosis. Smurf1 -/- mice on the other hand show an increase in bone density as they age, while being viable and fertile. Therefore, Smurf1 is a promising drug target to treat osteoporosis. This paper reports the discovery, synthesis, and biochemical characterization of highly selective Smurf1 inhibitors. We show that these compounds inhibit the catalytic HECT domain of Smurf1 with 500 nM IC 50 , but they do not inhibit closely related Smurf2 ligase, which is 80% identical to Smurf1. We show that Smurf1 inhibitors act by preventing the trans-thiolation reaction between Smurf1 and E2∼Ub thioesters. Our preliminary studies show that the C-lobe of Smurf1 alone does not contribute to the observed high selectivity of Smurf1 inhibitors.


  • Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites

    by Michael D. Olp, Daniel J. Sprague, Christopher J. Goetz, Stefan G. Kathman, Sarah L. Wynia-Smith, Shifali Shishodia, Steven B. Summers, Ziyang Xu, Alexander V. Statsyuk, Brian C. Smith

    BRD4, a member of the bromodomain and extraterminal domain (BET) family, has emerged as a promising epigenetic target in cancer and inflammatory disorders. All reported BET family ligands bind within the bromodomain acetyl-lysine binding sites and competitively inhibit BET protein interaction with acetylated chromatin. Alternative chemical probes that act orthogonally to the highly-conserved acetyl-lysine binding sites may exhibit selectivity within the BET family and avoid recently reported toxicity in clinical trials of BET bromodomain inhibitors. Here, we report the first identification of a ligandable site on a bromodomain outside the acetyl-lysine binding site. Inspired by our computational prediction of hotspots adjacent to nonhomologous cysteine residues within the C-terminal BRD4 bromodomain (BRD4-BD2), we performed a mid-throughput mass spectrometry screen to identify cysteine-reactive fragments that covalently and selectively modify BRD4. Subsequent mass spectrometry, NMR and computational docking analyses of electrophilic fragment hits revealed a novel ligandable site near Cys356 that is unique to BRD4 among human bromodomains. This site is orthogonal to the BRD4-BD2 acetyl-lysine binding site as Cys356 modification did not impact binding of the pan-BET bromodomain inhibitor JQ1 in fluorescence polarization assays nor an acetylated histone peptide in AlphaScreen assays. Finally, we tethered our top-performing covalent fragment to JQ1 and performed NanoBRET assays to provide proof of principle that this orthogonal site can be covalently targeted in intact human cells. Overall, we demonstrate the potential of targeting sites orthogonal to bromodomain acetyl-lysine binding sites to develop bivalent and covalent inhibitors that displace BRD4 from chromatin.


  • Open Access

    Front Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)

    by Yesid A. Ramirez, Thomas B. Adler, Eva Altmann, Theresa Klemm, Christian Tiesmeyer, Florian Sauer, Stefan G. Kathman, Alexander V. Statsyuk, Christoph Sotriffer, Caroline Kisker

  • Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis

    by Yesid Andres Ramirez, Thomas B. Adler, Eva Altmann, Theresa Klemm, Christian Tiesmeyer, Florian Sauer, Stefan G. Kathman, Alexander V. Statsyuk, Christoph Sotriffer, Caroline Kisker

    Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.


  • Open Access

    UbMES and UbFluor: Novel probes for ring-between-ring (RBR) E3 ubiquitin ligase PARKIN

    by Sungjin Park, Peter K. Foote, David T. Krist, Sarah E. Rice, Alexander V. Statsyuk